We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Sera Prognostics Inc (SERA) USD0.0001 A

Sell:$7.75 Buy:$8.90 Change: $0.65 (8.00%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$7.75
Buy:$8.90
Change: $0.65 (8.00%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$7.75
Buy:$8.90
Change: $0.65 (8.00%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.

Contact details

Address:
2749 E. Parleys Way, Suite 200
SALT LAKE CITY
84109
United States
Telephone:
+1 (801) 5050278
Website:
https://www.seraprognostics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SERA
ISIN:
US81749D1072
Market cap:
$276.26 million
Shares in issue:
33.77 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Evguenia Lindgardt
    President, Chief Executive Officer, Director
  • Austin Aerts
    Chief Financial Officer
  • Robert Harrison
    Chief Information Officer
  • John Boniface
    Chief Scientific Officer
  • Benjamin Jackson
    General Counsel
  • Paul Kearney
    Chief Data Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.